Drug Profile
MK 2206
Alternative Names: BIND 2206; BIND-2206-accurins; MK 2206 Accurin™; MK-2206; NSC-749607Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co; University of California at San Francisco
- Developer AstraZeneca; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
- Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Cyclobutanes
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Colorectal cancer; Haematological malignancies; Non-small cell lung cancer; Solid tumours
- No development reported Endometrial cancer; Neuroendocrine tumours
Most Recent Events
- 15 Sep 2020 No development reported - Phase-II for Endometrial cancer (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT01307631)
- 30 Jun 2017 National Cancer Institute completes a phase II trial in Endometrial cancer (Recurrent, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT01312753)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom (PO, Tablet)